Castle Biosciences (CSTL) Other Non Operating Income (2018 - 2026)

Castle Biosciences (CSTL) posted Other Non Operating Income of -$153000.0 for Q2 2026, up 65.15% sequentially from -$439000.0 in Q1 2026.

Castle Biosciences (CSTL) Other Non Operating Income (2018 - 2026) Analysis & Trends

Castle Biosciences has reported Other Non Operating Income for 5 years, with the latest figure at -$153000.0 in Q2 2026.

Quarterly Other Non Operating Income changed N/A year-over-year to -$153000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$448000.0 (changed N/A YoY) and the FY2025 annual result came in at $144000.0, changed N/A from the prior year.
Other Non Operating Income advanced to -$153000.0 in Q2 2026 per CSTL's latest filing, from -$439000.0 in the prior quarter.
Over five years, Other Non Operating Income peaked at $96000.0 in Q4 2025 and troughed at -$439000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Thermo Fisher Scientific	213.44 Bn	209.37 Bn	8.34 Bn
2	Danaher	139.95 Bn	135.60 Bn	3.61 Bn
3	Idexx Laboratories	46.16 Bn	45.96 Bn	779.09 Mn
4	Agilent Technologies	39.67 Bn	37.87 Bn	990.00 Mn
5	Iqvia Holdings	39.29 Bn	37.21 Bn	1.44 Bn
6	Natera	38.61 Bn	37.51 Bn	696.04 Mn
7	Illumina	29.99 Bn	28.82 Bn	770.00 Mn
8	Mettler Toledo International	28.57 Bn	28.51 Bn	650.22 Mn
9	Quest Diagnostics	26.17 Bn	25.55 Bn	1.03 Bn
10	Castle Biosciences	919.57 Mn	652.76 Mn	79.85 Mn

Download Data